(secondQuint)Taxotere, Followed by Myocet and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer.

 Phase II, open, not randomized clinical trial, to evaluate the sequential Taxotere(R), followed by Myocet(R) and Cyclophosphamide first line treatment in her2 negative breast cancer patients.

 The purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere(R) (T) followed by Myocet(R) (M)and Cyclophosphamide (MC) first line treatment in HER2 negative brest cancer patients.

.

 Taxotere, Followed by Myocet and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer@highlight

The purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere(R) (T) followed by Myocet(R) (M)and Cyclophosphamide (MC) first line treatment in HER2 negative brest cancer patients.

